The upsized ATM facility adds overhang and signals continued cash burn ahead of Phase 3 data in mid-2027. Monitor daily volume and price action for signs of accelerated selling; the stock may face persistent downward pressure as the ATM is utilized.
Price Chart
Executive Summary
Stoke Therapeutics filed a 424B5 prospectus supplement to upsize its at-the-market (ATM) equity offering facility from $150M to $200M, replacing the prior March 2026 supplement. The company has already raised $146.4M in net proceeds from prior sales under the same Cantor Fitzgerald agreement. This filing signals ongoing dilution risk for existing shareholders, with new investors facing immediate dilution of $21.05 per share at the current price of $28.86.
Key Facts
- Stoke upsized its ATM offering to up to $200,000,000 in aggregate common stock sales, replacing the prior $150M facility.
- The company has already sold ~4.7 million shares for aggregate net proceeds of $146.4 million under the prior supplement.
- At the assumed offering price of $28.86 per share, new investors would incur immediate dilution of $21.05 per share.
- Proceeds are earmarked for general corporate purposes including R&D, clinical development, and commercialization preparations.
- Cantor Fitzgerald will receive up to 3.0% commission on gross proceeds as sales agent.
Financial Impact
Up to $200M in potential new equity issuance; $146.4M already raised under prior facility. New investors face $21.05/share dilution at $28.86 offering price.
Risk Factors
- Continued dilution from ATM sales could pressure the stock price.
- No minimum offering amount — the company may sell shares opportunistically at any price.
- High short interest (~25.2% of float) amplifies downside risk if selling accelerates.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 424B5 Filing (Primary) | 0001193125-26-330792 |
| Document: d137193dexfilingfees.htm | 0001193125-26-330792 |
| Document: 0001193125-26-330792-index-headers.html | 0001193125-26-330792 |
| Document: 0001193125-26-330792-index.html | 0001193125-26-330792 |
| Document: 0001193125-26-330792.txt | 0001193125-26-330792 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 19, 2026 6w ago | Insider Cluster | $33.03 $28.93 | ▼ −12.41% | ▼ −10.46% | $25.69 (−22.22%) |
Aug 3, 2026 8w ago | 8-K | $31.67 $30.89 | ▲ +2.46% | ▲ +1.22% | $25.69 (+18.88%) |
Aug 3, 2026 8w ago | 424B5 | $31.67 $30.89 | ▲ +2.46% | ▲ +1.22% | $25.69 (+18.88%) |
Jun 30, 2026 13w ago | 8-K | $32.72 $29.31 | ▼ −10.42% | ▼ −9.39% | $25.69 (−21.49%) |
May 7, 2026 21w ago | 8-K | $32.89 $30.01 | ▼ −8.76% | ▼ −8.78% | $25.69 (−21.89%) |
Apr 22, 2026 23w ago | DEFA14A | $34.93 $30.30 | ▼ −13.27% | ▼ −17.90% | $25.69 (−26.45%) |
Apr 7, 2026 25w ago | 8-K | $34.87 $32.96 | ▼ −5.48% | ▼ −14.02% | $25.69 (−26.33%) |
Mar 13, 2026 29w ago | Insider Cluster | $33.19 $35.05 | ▼ −5.60% | ▼ −2.02% | $25.69 (+22.60%) |
Mar 10, 2026 29w ago | Insider Cluster | $38.35 $34.87 | ▼ −9.07% | ▼ −8.92% | $25.69 (−33.01%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access